trending Market Intelligence /marketintelligence/en/news-insights/trending/i8oNM_KiM9bb1NICoWSGfQ2 content esgSubNav
In This List

Delaware court dismisses C.R. Bard's patent case against AngioDynamics

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


Delaware court dismisses C.R. Bard's patent case against AngioDynamics

AngioDynamics Inc. said the U.S. District Court for the District of Delaware dismissed C.R. Bard Inc.'s patent infringement case against the company.

The lawsuit, filed March 2015, claimed certain implantable port products made by AngioDynamics infringed on C.R. Bard's three patents. C.R. Bard, which was acquired by Becton Dickinson and Co. in a $24 billion deal, was seeking unspecified damages and other relief in the case.

AngioDynamics will maintain its focus on delivering products to its customers, the company's President and CEO Jim Clemmer said in a March 8 news release about the matter.

In May 2017, AngioDynamics filed a lawsuit against C.R. Bard for allegedly violating federal antitrust laws by tying the sales of its tip location devices with its own peripherally inserted central catheters.

Latham, N.Y.-based AngioDynamics provides minimally invasive medical devices for use in vascular access, peripheral vascular disease and oncology.